Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG:3378)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
31.98
+2.64 (9.00%)
Apr 29, 2026, 4:08 PM HKT
Market Cap 4.36B
Revenue (ttm) 102.38K
Net Income (ttm) -145.79M
Shares Out 136.22M
EPS (ttm) -1.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 155,500
Average Volume 131,885
Open 28.20
Previous Close 29.34
Day's Range 28.20 - 32.88
52-Week Range 13.48 - 32.94
Beta 0.84
RSI 63.18
Earnings Date Mar 27, 2026

About HKG:3378

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. develops and manufactures immunotherapies for cancer and autoimmune diseases. The company's products include antibody drugs, including monoclonal, bispecific, and antibody drug conjugates for immuno-oncology pathways. The company was incorporated in 2014 and is headquartered in Wuhan, China. [Read more]

Industry Marine Shipping
Sector Industrials
Founded 2014
Employees 55
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3378
Full Company Profile

Financial Performance

In 2025, HKG:3378's revenue was 92,000, a decrease of -95.82% compared to the previous year's 2.20 million. Losses were -131.01 million, 13.1% more than in 2024.

Financial numbers in CNY Financial Statements

News

There is no news available yet.